News
Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback